Summary
Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with highspecificity. The biotech company’s nanosensor works by reacting to low pH andilluminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue.This is intended to make it easier for surgeons to remove cancer cells while leavinghealthy, functional tissue intact.
Click Here
to read the full article
Click Here
to read the full article